The cell dissociation market size is expected to advance at a CAGR of 17.10% during 2022–2030, to reach USD 1,347 million by 2030. This can be ascribed to the rising focus on personalized medicine and the surging government support for cancer research.
The main role of personalized medicine is to treat patients on the basis of their physiological profile. Hence, the development of various novel tools and the usage of advanced technology help researchers in finding out information about disease-causing cellulites, which further aids in suitable drug identification and the development of more-accurate biomarkers. For instance, in 2022, Tempus, a precision medicine software company, announced its collaboration with a U.K.-based biopharmaceutical company GSK plc, for rapid disease detection from biobanks, for the development of medicine using the data.
Moreover, personalized medicine is responsible for the investigation of insights into diseases with the usage of advanced and innovative technology and it also helps in providing patients with the required treatment. The biomarkers are used for determining responses and risks of treatments received by the patients.
Additionally, in stem cell research and cell biology investigations, enzymes are used for tissue and cellular separation, and single-cell harvesting. The main aim of the dissociation procedure is to separate the functionally viable dissociated cells. The outcome majorly depends on the type of tissue, dissociation media utilized, age of the animal/human, enzyme concentration, temperature, and genetic alterations. Trypsin, elastase, hyaluronidase, and collagenase are among the most commonly employed enzymatic dissociation products.
Various advantages offered by biopharmaceuticals, such as potent action, fewer side effects, effectiveness, and higher potential to cure diseases instead of only treating symptoms, are the key factors boosting the market growth. Moreover, in the pharmaceutical and healthcare industries, the focus is increasing on research and development activities and expenditure. Also, several private players and government bodies are increasing funds with the emergence of advanced tissue dissociation enzymatic products. Various new drugs were approved in 2022, which include Briumvi for the treatment of relapsing forms of multiple sclerosis, Mounjaro for enhancing blood sugar control in diabetes, Elahere for the treatment of patients with recurrent ovarian cancer that is resistant to platinum therapy, and many more. Therefore, the increasing approval of biopharmaceutical products and their related advantages are expected to drive the growth of the market.
The APAC market is expected to witness the highest CAGR, of 17.9%, in the coming years. This can be attributed to the various funding programs initiated by governments so as to create awareness about personalized medicine, the increasing demand for such drugs, and the surging cases of cancer in the region. Moreover, the regional market is further driven by the growing geriatric population, the increasing demand for isolation products, and the surging investments in R&D. For instance, the number of cancer cases in 2022 was around 1,500,000 in APAC.
The most-significant cell dissociation market players are Thermo Fisher Scientific Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, STEMCELL Technologies Canada Inc., PromoCell GmbH, VitaCyte LLC, Gemini BioProducts LLC, Innovative Cell Technologies Inc., Worthington Biochemical Corporation, and Capricorn Scientific.